Log In Get Started

News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Endeavour Silver's Q2 silver production rose 31% and gold production 35%, fueling a 336% year-over-year jump in mine operating cash flow.
  • United States Lime & Minerals reported 8.3% Q2 revenue growth and declared a $0.06 quarterly cash dividend on strong construction and steel demand.
  • Hawthorn Bancshares' net income rose 20.1% to $7.3 million in Q2, supported by wider net interest margins and a dividend increase.
  • Algoma Steel posted $13.8 million adjusted EBITDA and said its second EAF unit nears first steel in Q3 despite U.S. Section 232 tariff headwinds.
  • HII won approximately $76.6 billion in U.S. Navy contracts to build five Columbia-class and nine Virginia-class submarines plus shipyard infrastructure funding.
  • Analyst rates NIO a tactical buy, citing delivery momentum and improving margins with a mid-term $7 price target and disciplined stop.

Latest Articles

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
May 15, 2026
Maya Rios
Press Releases

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

CG Oncology reported positive interim results from its Phase 2 CORE-008 Cohort CX trial evaluating the combination of cretostimogene grenadenorepvec with gemcitabine in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are BCG-exposed or BCG-unresponsive. The study showed high complete response rates, strong high-grade event-fr…

CGON
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
May 15, 2026
Priya Menon
Press Releases

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

UroGen Pharma reported that its investigational drug UGN-103 achieved a 94.5% six-month durability of response in the ongoing Phase 3 UTOPIA trial for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The results align closely with the performance of ZUSDURI, the company's FDA-approved treatment i…

URGN
LifeMD to Participate in Upcoming Investor Conferences
May 15, 2026
Leila Farooq
Press Releases

LifeMD to Participate in Upcoming Investor Conferences

LifeMD, Inc., a leading virtual primary care platform, announced that its management will participate in the LD Micro Invitational XVI Conference and the B. Riley Securities 26th Annual Investor Conference in May 2026. The company aims to engage with investors through presentations and one-on-one meetings to discuss its telemedicine offerings and g…

LFMD
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
May 15, 2026
Caleb Monroe
Press Releases

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

Belite Bio announced an oral presentation at Retina China 2026 to showcase positive topline results from its Phase 3 DRAGON trial evaluating tinlarebant, an oral therapy for Stargardt disease type 1 (STGD1). Tinlarebant demonstrated a significant 35.7% reduction in atrophic retinal lesion growth and was well tolerated. The company is progressing re…

BLTE
GT Biopharma Reports First Quarter 2026 Financial Results
May 15, 2026
Derek Hwang
Press Releases

GT Biopharma Reports First Quarter 2026 Financial Results

GT Biopharma reported Q1 2026 financial results highlighting ongoing Phase 1 trials for GTB-3650 in hematologic malignancies and GTB-5550 in multiple solid tumor types. The company has approximately $9 million in cash, expected to fund operations through Q4 2026. Despite increased SG&A expenses leading to a larger net loss compared to last year, th…

GTBP
Lifeward Reports First Quarter 2026 Financial Results
May 15, 2026
Maya Rios
Press Releases

Lifeward Reports First Quarter 2026 Financial Results

Lifeward Ltd. announced its Q1 2026 financial results, highlighting the successful closing of its acquisition of Oratech alongside a $10 million financing. The acquisition adds $6.5 million in cash and advances Lifeward's Protein Oral Delivery platform, including the lead asset ORMD-0801 oral insulin set for Phase 2 trials. The company also acquire…

LFWD
Arcutis: Dermatology Revenue Is Turning into a Compounding Growth Engine
May 15, 2026
Marcus Reed
Trade Ideas

Arcutis: Dermatology Revenue Is Turning into a Compounding Growth Engine

Arcutis is transitioning from pure R&D to a commercial growth story. ZORYVE posted $105.4M in Q1 2026 revenue (65% YoY) and management reaffirmed 2026 guidance of $480-495M. With pediatric label expansion, new formulations and a broader sales effort, the business is starting to compound. The setup favors a long trade with defined risk controls whil…

ARQT
Keysight Q2: A Clean Beat-and-Raise Setup — Tactical Long into Results
May 15, 2026
Avery Klein
Trade Ideas

Keysight Q2: A Clean Beat-and-Raise Setup — Tactical Long into Results

Keysight looks set to beat and raise on Q2 results thanks to sustained AI infrastructure demand, strong defense spending and healthy cash generation. The stock is extended but technicals and low short interest favor an orderly rally into an earnings-print trade. Proposed trade: enter at $360.00, stop $340.00, target $405.00 over the next 45 trading…

KEYS
Buy On Holding After Q1 Beat: Margin Lift and a Cleaner Risk/Reward
May 15, 2026
Nina Shah
Trade Ideas

Buy On Holding After Q1 Beat: Margin Lift and a Cleaner Risk/Reward

On Holding reported a solid Q1 with double-digit revenue growth, margin expansion, and a raised EBITDA guide. The shares trade well below their 52-week high, carry a $12.2B market cap, and show improving technicals. This trade idea outlines an actionable long with entry, stop, and target aimed at capturing a recovery toward renewed multiple expansi…

ONON
Trump Says Taiwan Arms Sales Were Raised With Xi; Decision Expected Soon
May 15, 2026
Maya Rios
Stock Markets

Trump Says Taiwan Arms Sales Were Raised With Xi; Decision Expected Soon

President Donald Trump told reporters he discussed U.S. arms sales to Taiwan with Chinese President Xi Jinping during talks in Beijing and said he would make a decision on the matter soon. Speaking aboard Air Force One as he returned from China, Trump said the leaders "talked a lot about Taiwan," denied any conflict over the issue, made no commitme…